<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="the preparation of immune plasma to be used in the" exact="treatment" post="of patients with COVID-19 AccorsiPatriziaaBertiPierluigibde AngelisVincenzovincenzo.deangelis@asufc.sanita.fvg.itc*De SilvestroGiustinadMascarettiLucaeOstuniAngelofcollab: On behalf"/>
 <result pre="Passive immunotherapy with plasma derived from patients convalescent from SARS-CoV-2" exact="infection" post="can be a promising approach in the treatment of"/>
 <result pre="from SARS-CoV-2 infection can be a promising approach in the" exact="treatment" post="of COVID-19 patients. It is important that Blood Establishments"/>
 <result pre="with plasma derived from patients that have recovered from SARS-CoV-2" exact="infection" post="can be a promising approach in the treatment of"/>
 <result pre="from SARS-CoV-2 infection can be a promising approach in the" exact="treatment" post="of COVID-19 patients, as suggested by recent experiences [[1],"/>
 <result pre="last years [6]. Therefore, collection of convalescent plasma for the" exact="treatment" post="of COVID-19 patients has started in different countries (among"/>
 <result pre="use. This â€œposition paperâ€� is not a protocol for the" exact="treatment" post="of patients with COVID-19 by means of convalescent plasma:"/>
 <result pre="focused, at present, on patients with a very recent documented" exact="infection" post="by SARS-CoV-2 who volunteer, upon informed consent, to undergo"/>
 <result pre="collected by apheresis from patients recently recovered from laboratory confirmed" exact="infection" post="by SARS-CoV-2 (either hospitalised or self-isolated at home) with"/>
 <result pre="in place) is a further negative result of a NAT" exact="testing" post="on a nasopharyngeal swab and on serum/plasma, performed 14"/>
 <result pre="large number of people who have recovered from an asymptomatic" exact="infection" post="(or from a disease with minor clinical signs); many"/>
 <result pre="asymptomatic carriers of the virus. As soon as a serology" exact="testing" post="is available, the demonstration in their sera of an"/>
 <result pre="provisions on donor selection. Their recruitment can easily follow a" exact="screening" post="for SARS-CoV-2 (eventually followed by a titration of the"/>
 <result pre="collecting plasma from regular donors. A negative result of NAT" exact="testing" post="for SARS-CoV-2 is also clearly expected in both cases."/>
 <result pre="effects in the interaction with other drugs used in the" exact="treatment" post="of COVID-19. In the absence of any conclusion, immune"/>
 <result pre="the administration of human plasma can also take place in" exact="treatment" post="with this product; in particular Blood Establishments should remind"/>
 <result pre="to make possible epidemiologic evaluation as soon as validated serology" exact="testing" post="is available. We also recommend collection of any data"/>
 <result pre="6Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
 <result pre="YOYCheng Y.WongR.Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone" exact="treatment" post="in SARS patientsClin Microbiol Infect10200467667815214887 16ArabiY.BalkhyH.HajeerA.H.Feasibility, safety, clinical, and"/>
</results>
